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A number of 5′-O-dicarboxylic fatty acyl monoester derivatives of 3'-azido-3'-deoxythymidine
(zidovudine, AZT), 2',3'-didehydro-2',3'-dideoxythymidine (stavudine, d4T), and 3'-fluoro-3'deoxythymidine (alovudine, FLT) were synthesized to improve the lipophilicity and potentially
the cellular delivery of parent polar 2′,3′-dideoxynucleoside (ddN) analogs. The compounds
were evaluated for their anti-HIV activity. Three different fatty acids with varying chain length
of suberic acid (octanedioic acid), sebacic acid (decanedioic acid), and dodecanedioic acid were
used for the conjugation with the nucleosides. The compounds were evaluated for anti-HIV
activity and cytotoxicity. All dicarboxylic ester conjugates of nucleosides exhibited significantly
higher anti-HIV activity than that of the corresponding parent nucleoside analogs. Among all the
tested conjugates, 5′-O-suberate derivative of AZT (EC50 = 0.10 nM) was found to be the most
potent compound and showed 80-fold higher anti-HIV activity than AZT without any significant
toxicity (TC50 > 500 nM).
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Highly Active Antiretroviral Therapy (HAART) for the
treatment for human immunodeficiency virus (HIV) includes
using different classes of anti-HIV agents, including nucleoside
reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse
transcriptase inhibitors (NNRTIs) along with protease inhibitors
(Agarwal, 2008). 2′,3′-Dideoxynucleoside (ddN) analogs are
similar to naturally occurring nucleosides, but they cannot be
used for the synthesis of new DNA as they lack the 3′-hydroxyl
group. These agents act as nucleoside reverse transcriptase
inhibitors (NRTIs) and thereby cause DNA chain termination.
NRTIs have shown severe adverse effects, mitochondrial
toxicity, and resistance to multi-drug resistant HIV.1-4
Furthermore, nucleoside analogs are polar in nature and have
limited cellular uptake. Novel anti-HIV agents are urgently
needed with a better safety and resistance profile for the
prevention and treatment of HIV infection.

transmitted organisms., Microbicides which are focused on the
prevention of HIV transmissiontarget vaginal, cervical or rectal
mucosa and may act via several mechanisms, such as the nonspecific direct inactivation of the virus.6 Currently known
microbicides
in
development,
such
as
UC-781
(thiocarboxanilide), TMC-120 (dapivirine), MIV-150, and
tenofovir, act specifically via a single mechanism of the
inhibition of reverse transcriptase enzyme.7 Thus, they have the
potential to induce viral resistance and are less effective against
cell-associated virus. Developing new anti-HIV microbicides that
are multifunctional anti-HIV agents is urgently needed to reduce
the incidence of drug resistance. Furthermore, the lipophilic
microbicides could bind tightly or irreversibly to the HIV
envelope, leading to inactivation of cell-free, or cell-associated
virus or both resulting in a significant decrease in virus
transmission.

Prevention of HIV transmission to women is essential to
avoid transmission of the virus to the newborn. Currently there
are no vaccines developed to provide protection against HIV.
Thus, it is a necessity to develop additional safe, effective
treatment and preventative strategies.

Furthermore, there have been several reports on lipids acting
as antiviral and antibacterial agents.8 The medium length chain
saturated fatty acids are one of those agents that inhibit
enveloped viruses like HIV and herpes simplex virus type 1
(HSV-1).9 Microbicidal hydrogels of these fatty acids have been
developed and evaluated, and they possibly act by disrupting the
viral lipid membrane.9 HIV-1 replication is inhibited by
heteroatom substituted myristic acid analogs without showing
any significant cellular toxicity. Myristoylated HIV proteins
include PR160gag-pol, Pr55gag, p17gag, and p27nef. Myristic acid
analogs inhibit the N-myristoyl transferase (NMT) that catalyzes
the N-myristoylation of HIV proteins.10 2-Methoxydodecanoic
acid, 4-oxatetradecanoic acid, and 12-thioethyldodecanoic acid
have shown to reduce HIV-1 replication in acutely infected
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Microbicidal agents are agents which are topically applied to
the vagina or rectum prevent the transmission of sexually
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Scheme 1. Synthesis of 5′–mono-substituted fatty acyl ester nucleoside conjugates of FLT, AZT, and d4T (1-6).
T-lymphocytes.11 For example, 12-thioethyldodecanoic acid
derivative was moderately active (EC50 = 9.4 µM) against HIVinfected T4 lymphocytes.
Several studies have demonstrated the use of lipids as active
intravaginal microbicide agents to protect against various
sexually transmitted infections (STIs).8-10 When lipid-associated
drugs are administered subcutaneously, they are usually
distributed throughout the lymphoid system with improved
stability, and the drug can be delivered at higher concentrations.12
This is a major advantage since HIV is hidden in the lymphatic
system not accessible by many commercially available polar antiHIV nucleosides.
Thus, designing lipophilic anti-HIV nucleosides for
developing anti-HIV agents or anti-HIV microbicides is a subject
of major interest. The most predominant approach to this strategy
is the esterification strategy between nucleosides and fatty acids.
The in vitro chemical stability of ester conjugates helps to
produce formulations with adequate shelf lives. The esters also
act as the substrates for esterase enzyme and, therefore, are labile
in vivo.13 The 5′-O-hydroxyl esterification of the anti-HIV
nucleosides also provides a viable approach to increase cellular
delivery of polar nucleosides. We have previously shown that
fatty acyl monocarboxylic ester derivatives of 3'-azido-3'deoxythymidine
(zidovudine,
AZT),14,15
3'-fluoro-3'16
deoxythymidine
(FLT),
(-)-2',3'-dideoxy-3'-thiacytidine
(3TC),17 5-fluoro-(-)-2',3'-dideoxy-3'-thiacytidine (FTC),18 and
2',3'-didehydro-2',3'-dideoxythymidine (stavudine, d4T)19 with
enhanced anti-HIV activity against CXC4-tropic, CCR5-tropic
cell-associated, and/or multi-drug resistant strains of virus. The
fatty acid substitution with FTC and 3TC showed a significant
increase in their cellular uptake in comparison to their parent
nucleosides.17,18
Herein, we report the synthesis and evaluation of novel 5′-Ofatty acyl ester derivatives of AZT, d4T, and FLT using

dicarboxylic fatty acids. As shown before for other conjugates,
fatty acids were expected to improve the lipophilicty of polar
nucleoside analogs and cellular uptake and to generate lipophilic
agents with higher anti-HIV activity. Dicarboxylic acids instead
of monocarboxylic fatty acids were selected to generate more
amphipathic property in the structure of conjugates due to the
presence of additional polar free carboxylic acid.
The synthesis of seven mono-substituted 5′-O-(fatty
acyl)esters of nucleosides is shown in Scheme 1. Three
nucleosides, FLT, AZT, and d4T, and three different dicarboxylic
fatty acids were used for esterification. The conjugates were
synthesized by reacting nucleosides and dicarboxylic fatty acids
in N,N-dimethylformamide (DMF) in the presence of 2-(1Hbenzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU), 1-hydroxybenzotriazole (HOBt)
and diisopropylcarbodiimide (DIC) as coupling reagents and
N,N-diisopropylethylamine (DIPEA) as a base. The reaction
mixtures were stirred at room temperature overnight. The final
products were purified by HPLC on C-18 column using water
and acetonitrile as the solvent system in order to achieve more
than 95% purity. The chemical structures of the final products
were characterized by nuclear magnetic resonance spectrometry
(1H NMR and 13C NMR), and were confirmed by a high–
resolution time-of-flight electrospray mass spectrometer.
All the synthesized conjugates were evaluated for their
inhibitory activity of HIV–1 (subtype B, US/92/727) replication
in human peripheral blood mononuclear (PBMC) cells.20 Table 1
illustrates the anti-HIV-1 activity (EC50) and cytotoxicity (TC50)
of the nucleoside ester conjugates compared with their
corresponding parent nucleosides. No cytotoxicity was observed
up to the highest tested concentration for both the parent
nucleosides and the synthesized conjugates (TC50 > 500 nM) (17).
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Table 1. Anti-HIV activity of dicarboxylic acid ester conjugates of nucleoside conjugates (1-7).
PBMC/HIV-1US/92/727
Compd.

Chemical Name

AZT

Log Pd
EC50 (nM)a

TC50 (nM)b

TIc

3'-azido-2',3'-dideoxythymidine

8.00

>1000

>125

-0.24e

FLT

3'-fluoro-2',3'-deoxythymidine

2.00

>500

>250

-0.41

d4T

2',3'-didehydro-2',3'-dideoxythymidine

90.0

>500

>5.6

-0.34

1

8-[(3′-azido-2′,3′-dideoxythymidinyl)-5′-yl]octandioate

0.10

>500

>5000

1.97e

2

10-[(3′-azido-2′,3′-dideoxythymidinyl)-5′-yl]decandioate

0.31

>500

>1613

3.03e

3

12-[(3′-azido-2′,3′-dideoxythymidinyl)-5′-yl]dodecandioate

0.33

>500

>1516

4.09e

4

10-[5′-O-(3′-fluoro-2′,3′-dideoxythymidinyl)]decandioate

0.26

>500

>1923

1.99

5

12-[5′-O-(3′-fluoro-2′,3′-dideoxythymidinyl)]dodecandioate

0.25

>500

>2000

2.83

6

10-[(2',3'-didehydro-2',3'-dideoxythymidine)-5′-yl]decandioate

1.98

>500

>253

2.06

7

12-[(2',3'-didehydro-2',3'-dideoxythymidine)-5′-yl]dodecandioate

18.30

>500

>27

2.90

a

EC50 (50% effective concentration), All the assays were carried out in triplicate (n = 3); bTC50 (50% toxic concentration), All
the assays were carried out in triplicate (n = 3); cTherapeutic index(TC50/EC50); dCalculated Partition coefficient by ChemDraw
Ultra 12.0; eCLogP calculated by ChemDraw Ultra 12.0.
The AZT conjugates (1-3, EC50 = 0.1-0.3 nM) exhibited
consistently higher anti-HIV activity than that of AZT (EC50 =
8.0 nM). For example, octandioate (suberate) ester derivative of
AZT (1, EC50 = 0.1 nM) showed 80 times higher anti-HIV
activity than the parent nucleoside. AZT conjugates having
longer chain fatty acids also showed enhancement in anti-HIV
activity than AZT while the ratio of improvement was less than
that of compound 1. The decandioate ester of AZT (2, EC50 =
0.31 nM) was 26-fold more potent than that of AZT. The activity
of dodecandioate ester of AZT (3) was 24 times higher when
compared to AZT. Among the AZT conjugates, AZT-suberate
conjugate (1) showed the highest anti-HIV activity. These data
suggest that conjugation of AZT with dicarboxylic acids
significantly enhances the anti-HIV activity with higher potency
seen in conjugates with shorter chain length.
Similarly, dicarboxylic ester conjugates of d4T (6 and 7, EC50
= 1.98-18.3 nM) showed better anti-HIV activity from that of
d4T (EC50 = 90 nM) in the PBMC assay against HIV–1US/92/727.
The decanedioate ester of d4T (6, EC50 = 1.98 nM) exhibited 45
times more anti-HIV activity than d4T. The dodecandioate ester
of d4T (7, EC50 = 18.3 nM) showed 5 times higher anti-HIV
activity when compared to that of its parent nucleoside. These
results indicate that the anti-HIV activity of the carboxylic esters
of nucleoside depends on the chain length of the carboxylic acid,
and shorter length dicarboxylate monoester conjugates are more
potent.
A similar trend was observed for FLT ester conjugates
compared to the parent nucleoside. Amongst all the FLT
conjugates (EC50 = 0.25-0.26 nM), the decanedioate ester of FLT
(4, EC50 = 0.26 nM) and dodecanedioate ester of FLT (5, EC50 =
0.25 nM) showed an 8-fold increase in anti-HIV activity when
compared to FLT (EC50 = 2 nM), but the difference in anti-HIV
activity between the two conjugates was not significant.

There was a significant increase in the therapeutic index of
AZT and FLT derivatives when compared to that of the
respective parent nucleosides. The increased therapeutic index
indicates synergistic effect of conjugation of dicarboxylic acids
with ddNs. Among all the synthesized dicarboxylic acid ester
derivatives of AZT, FLT, and d4T, the decandioate monoester
conjugate of AZT (1) showed the highest anti-HIV activity.
This study indicates that NRTIs when in conjugation with
long chain dicarboxylic acids exhibit higher anti-HIV activity
possibly due to the improved lipophilicity thereby increasing the
cellular uptake of NRTIs. As shown by calculated partition
coefficient values (Table 1), the ester conjugates were more
lipophilic that their parent analogs. We have shown previously
for other fatty acyl derivatives of nucleosides that the highly
lipophilic conjugates could have higher cellular uptake
contributing to their improved anti-HIV activity.17,18However, for
dicarboxylic monoester conjugates, an appropriate lipophilicty is
required for an optimal anti-HIV activity since highly lipophilic
conjugates with longer chain length were less potent than those
with shorter chain length. We have previously shown higher
cellular uptake and the intracellular hydrolysis of several fatty
acyl ester derivatives of 3TC, d4T, and FTC.17-19 Similarly, it is
expected that when the conjugate esters enter the cells, they
undergo intracellular hydrolysis by esterases and release the antiHIV nucleosides and fatty acids targeting different stages of the
HIV life cycle possibly contributing to enhanced anti-HIV
activity. Nucleoside and fatty acid analogs are known to target
the reverse transcriptase and the NMT enzymes. More
mechanistic studies are required to determine the exact
mechanism of activity of the ester conjugates of the nucleosides.
In conclusion, several lipophilic 5′-O-fatty acyl dicarboxylic
monoester derivatives of the nucleoside reverse transcriptase
inhibitors, AZT, FLT, and d4T were synthesized and evaluated
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for their anti-HIV activity. The fatty acid substitution at the 5′O-position enhanced the lipophilicity of the anti-HIV nucleoside
analogs. All conjugates exhibited higher anti-HIV activity when
compared to their parent nucleosides. The improved viral
inhibition by the AZT, d4T, and FLT fatty acyl derivatives versus
the parent nucleoside is presumably due to the enhanced cellular
uptake of the lipophilic conjugates. These conjugates have the
potential to be used as potent anti-HIV agents and/or lipophilic
anti-HIV microbicides after further optimization.
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